<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" version="2.0">
  <channel>
    <title>Mail.com: Baxter International Inc.</title>
    <link>http://www.mail.com/companies/185774-baxter-international-inc.html</link>
    <description>Mail.com - the best personalized free web-based Email</description>
    <language>en</language>
    <dc:language>en</dc:language>
    <image>
      <title>Mail.com: Baxter International Inc.</title>
      <url>http://sec-s.uicdn.com/mail.com/2.28/img/mailcom_logo_rss.png</url>
      <link>http://www.mail.com/companies/185774-baxter-international-inc.html</link>
    </image>
    <item>
      <title>Baxter drug fails to slow Alzheimer's in big study</title>
      <link>http://www.mail.com/scitech/health/2068290-baxter-drug-fails-to-slow-alzheimers-big-study.html</link>
      <description>DEERFIELD, Ill. (AP) — Baxter International Inc. says that a blood product it was testing failed to slow mental decline or to preserve physical function in a major study of 390 patients with mild to moderate Alzheimer's disease. 
                   The company says that people who received 18 months of infusions with its drug, Gammagard, fared no better than others given inf...</description>
      <pubDate>Tue, 07 May 2013 13:48:16 GMT</pubDate>
      <guid isPermaLink="false">http://www.mail.com/scitech/health/2068290-baxter-drug-fails-to-slow-alzheimers-big-study.html</guid>
      <dc:date>2013-05-07T13:48:16Z</dc:date>
    </item>
    <item>
      <title>Lilly plans another study for Alzheimer's drug</title>
      <link>http://www.mail.com/scitech/health/1760836-lilly-plans-study-alzheimers-drug.html</link>
      <description>INDIANAPOLIS (AP) — Eli Lilly's experimental Alzheimer's drug has flashed potential to help with mild cases of the disease, but patients and doctors will have to wait a few more years to learn whether regulators will allow the drugmaker to sell it. 
                   Lilly said Wednesday that it will launch another late-stage study of the drug, solanezumab, no later than ne...</description>
      <pubDate>Wed, 12 Dec 2012 20:42:00 GMT</pubDate>
      <guid isPermaLink="false">http://www.mail.com/scitech/health/1760836-lilly-plans-study-alzheimers-drug.html</guid>
      <dc:date>2012-12-12T20:42:00Z</dc:date>
    </item>
    <item>
      <title>Baxter to buy Swedish firm Gambro in $2.76B deal</title>
      <link>http://www.mail.com/scitech/health/1742876-baxter-to-buy-swedish-firm-gambro-276b-deal.html</link>
      <description>DEERFIELD, Ill. (AP) — Drug and medical device maker Baxter International plans to buy the privately held Swedish company Gambro AB for about $2.76 billion to broaden its dialysis product portfolio. 
                   Gambro makes dialysis products for patients with acute or chronic kidney disease, and Baxter said it had sales of about $1.6 billion last year. Baxter Interna...</description>
      <pubDate>Tue, 04 Dec 2012 21:29:00 GMT</pubDate>
      <guid isPermaLink="false">http://www.mail.com/scitech/health/1742876-baxter-to-buy-swedish-firm-gambro-276b-deal.html</guid>
      <dc:date>2012-12-04T21:29:00Z</dc:date>
    </item>
  </channel>
</rss>

